Loading clinical trials...
Loading clinical trials...
This study is designed to examine whether olanzapine (2.5 to 20mg/day) impacts opioid use in patients with opioid use disorder and comorbid SMI symptoms who are taking buprenorphine-naloxone. The spec...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of Pennsylvania
NCT04587791 · Chronic Pain, Opioid Use Disorder
NCT07421102 · Opioid Use Disorder
NCT05492825 · Substance Use Disorders, Chronic Pain, and more
NCT05942313 · Opioid Use Disorder, Pregnancy Related
NCT07466784 · Opioid Use Disorder, Opioid Abuse or Dependence, and more
University of Pennsylvania
Philadelphia, Pennsylvania
Virginia Commonwealth University
Richmond, Virginia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions